TNFSF8-Targeting CpG Peptide Vaccine

A **TNFSF8-Targeting CpG Peptide Vaccine** is an experimental therapeutic vaccine designed to stimulate anti-tumor immune responses by targeting TNFSF8 (also known as CD153 or CD30 ligand), an immunoregulatory molecule important in T cell activation, using a synthetic peptide derived from its sequence and formulated with a CpG oligodeoxynucleotide adjuvant. CpG motifs activate Toll-like receptor 9 (TLR9) on antigen-presenting cells, amplifying antigen-specific CD8+ T cell responses critical for immunotherapy. TNFSF8’s biological role includes regulating immune cell activation and proliferation via interaction with the CD30 receptor, with implications in cancer and infection. This vaccine is conceptualized primarily for use in oncology settings as a peptide-based immunotherapy.